Nektar Therapeutics · Transaction Jun 21, 2018 · Filed Oct 2, 2018 · $1,001 to $15,000
NASDAQ NMS - GLOBAL MARKET · NKTR
-1.26% · -$0.8600 · Vol 2.8M
Market closed · last close 4:00 PM ET · price as of 18:58:09 ET
Nektar Therapeutics
Pharmaceuticals
$67.50
Follow $NKTR
One email when a member of Congress discloses a trade in it, with the official filing receipt linked.
Free. No account. Unsubscribe in one click.
Follow $NKTR by emailVeridion Score
BETAMEDIUM CONF · 6 of 6 factors measuredSat Sep 19 · market closed · Markets closed · resumes Mon 9:30 ET · NKTR
MethodologyNKTR
Nektar Therapeutics
Sat Sep 19 · market closed · Markets closed · resumes Mon 9:30 ET
Middle range
Highest qualified requires a score of at least 75 and high confidence, including full factor coverage. Upper range can hold a higher score with lower confidence.
Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.
53/ 100
Veridion Score
Middle range · MEDIUM confidence · 6 of 6 factors measured
Sovereign · $25/mo
See why this score moved.
- · Factor breakdown with raw signals
- · Day-over-day delta + driver
- · Factor coverage readout
- · Valuation · hype · market flow
- · Pro Chart event markers
- · Score history + alerts
Start Sovereign · $25/mo →
Cancel anytime · or Reserve · $79/mo
Confidence: MEDIUM · 6 of 6 factors measured · Sat Sep 19 · market closed · Markets closed · resumes Mon 9:30 ET
Veridion Score History · 90D
Loading score history
AI Analysis
SovereignWhy is NKTR moving today?
Sovereign unlock connects news, insider activity, analyst moves, and live price action.
About Nektar Therapeutics
PHARMACEUTICAL PREPARATIONSListed since
1994
Employees
63
Country
US
Nektar Therapeutics is a clinical-stage, research-based biopharmaceutical company headquartered in San Francisco, California, and incorporated in Delaware, focused on discovering and developing medicines in the field of immunotherapy. The Company directs its efforts toward creating immunomodulatory agents that selectively induce, amplify, attenuate, or prevent immune responses to achieve desired therapeutic outcomes. Its pipeline of clinical-stage and preclinical-stage immunomodulatory agents targets the treatment of autoimmune diseases, including rezpegaldesleukin, NKTR-0165, NKTR-0166, and NKTR-422, as well as cancer, including NKTR-255.
Key statistics
Reported fields plus Veridion-computed history. Unsourced tiles are omitted.
Open
$68.00
Day high
$69.09
Day low
$66.98
Previous close
$68.36
52W high
$100.35
-32.74% from high
52W low
$35.12
50% of range
Market cap
$2.3B
EPS
$-7.8700
Beta
1.03
Shares out
34.1M
Volume
2.8M
3.76× rel vol
Avg volume
747.4K
VWAP
$67.35
Price history computed in-house
1W
-3.24%
1M
-9.43%
3M
+10.69%
1Y
+22.42%
YTD
+59.65%
SMA 50 $71.66 · below
SMA 200 $65.35 · above
52W position 50%
NKTR overview
Related filings and maps
Public disclosures
Congress activity in NKTR
Official filing ↗
Nektar Therapeutics · Transaction Jun 6, 2018 · Filed Oct 2, 2018 · $1,001 to $15,000
Federal contracts
NKTR contract awards, year to date.
Public federal awards linked to this ticker.
Not disclosed
Refresh interval: 12hSource: Federal contract awards
No federal contracts on file for NKTR in this window.
Lobbying spend
NKTR lobbying filings, year to date.
Registered lobbying filings matched to Nektar Therapeutics.
Not disclosed
Refresh interval: 12hSource: LDA disclosure filings
No lobbying filings on file for NKTR in this window.
Analyst ratings
Sovereign unlock shows live analyst consensus for NKTR.
Options
Sovereign unlock shows live options positioning for NKTR.